×

Video Interview: Keith R. Dunleavy, M.D., Chief Executive Officer and Chairman, Inovalon [INOV] NASDAQ CEO Signature Series Broadcasted From the NASDAQ MarketSite

NEW YORK, March 16, 2015 (GLOBE NEWSWIRE) -- Veteran business journalist Kelsey Hubbard joins Keith R. Dunleavy, M.D., Chief Executive Officer and Chairman, Inovalon [INOV] to discuss the company's industry, strategy, financials and positioning.

Click here to view video: http://edge.media-server.com/m/p/ut99qso5

Keith R. Dunleavy, M.D., Chief Executive Officer and Chairman of the Board

Dr. Dunleavy has served as Inovalon's Chief Executive Officer since his organization of the company's predecessor companies in 1998, as Chairman of the board of directors since the creation of the board in 2006, and as President from the Company's foundation until May of 2014. Dr. Dunleavy is responsible for the overall execution of the company's business plan, strategic relationships, and the identification and realization of company product strategy and vision.

During his tenure at Inovalon, Dr. Dunleavy has worked extensively with a wide array and number of healthcare organizations, regulatory and oversight bodies, and technology companies examining the growing role of data within healthcare, and its ability to drive meaningful insight and improvement for its constituents. Driven by a vision of data's ability to drive insight and improvement in healthcare, Dr. Dunleavy has lead Inovalon from its origins to its current industry-leading position leveraging advanced, cloud-based analytical and data-driven intervention platforms which are informed by data pertaining to more than 754,000 physicians, 248,000 clinical facilities, 120 million Americans, and 9.2 billion medical events providing a powerful platform that enables high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, consumers and pharma/life-sciences researchers.

Dr. Dunleavy received a Bachelor's degree in Biology modified with Engineering with High Honors from Dartmouth College where his studies and work focused upon the neurosciences, computer sciences and electrical engineering with his honors thesis focused on the computer simulation of artificial human cerebellar functional units. Dr. Dunleavy earned his doctorate in medicine from Harvard Medical School, completed his medical residency at The Johns Hopkins Hospital in Baltimore, Maryland, practiced and was Board Certified in Internal Medicine. He serves as a Director on the Dartmouth Medical School Board of Overseers, has authored or co-authored a number of scientific journal articles, abstracts, and proprietary research papers, and has presented his work and materials at multiple national and international conferences.

About Inovalon:

Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Inovalon's unique achievement of value is delivered through the effective progression of Turning Data into Insight, and Insight into Action®. Large proprietary datasets, advanced integration technologies, sophisticated predictive analytics, data-driven intervention platforms, and deep subject matter expertise deliver a seamless, end-to-end capability that brings the benefits of big data and large-scale analytics to the point of care. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while bringing to bear the unique capabilities to resolve them. Providing technology that supports hundreds of healthcare organizations in 98.2% of U.S. counties and Puerto Rico, Inovalon's cloud-based analytical and data-driven intervention platforms are informed by data pertaining to more than 754,000 physicians, 248,000 clinical facilities, and more than 120 million Americans providing a powerful solution suite that drives high-value impact, improving quality and economics for health plans, ACOs, hospitals, physicians, consumers and pharma/life-sciences researchers. For more information, visit www.inovalon.com

For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 888/534-0565.

Source: NASDAQ CEO Signature Series;Inovalon